PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Fludarabine

Drugs in development · updated 30 October 2026

Fludarabine: clinical trials and development status

Other names and codes: Fludara, Oforta

FDA verified identityApproved in the US (FDA)

As of 30 October 2026 Fludarabine is in 482 active clinical trials (recruiting or ongoing, phases I–III) for 264 diseases. The most advanced phase is III.

482Active trials
IIIMost advanced phase
264Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Fludarabine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 264 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII89NCT05183035
Precursor lymphoblastic lymphoma/leukemiaIII61NCT05457556
Myelodysplastic SyndromesIII58NCT05457556
Non-Hodgkin lymphomaII–III37NCT06756152
Chronic lymphocytic leukemiaIII32NCT02048813
Multiple myelomaIII29NCT06615479
Acute biphenotypic leukaemiaIII22NCT05457556
Burkitt lymphomaIII22NCT07223021
Follicular lymphomaIII21NCT05371093
LeukemiaIII18NCT05477589
Chronic myelomonocytic leukemiaII–III15NCT04708054
Autoimmune diseaseII–III12NCT06154252
MyositisII–III11NCT06154252
NeoplasmIII11NCT05477589
Systemic sclerodermaIII10NCT07335562
Residual neoplasmIII9NCT02724163
Myeloid leukemiaII–III7NCT07157514
Synovial sarcomaIII6NCT07174427
DermatomyositisII–III3NCT06154252
Precursor B-cell lymphoblastic leukemiaII–III3NCT03937544
Acute myelomonocytic leukemiaII–III2NCT06756152
AnemiaIII2NCT02048813
Hematologic neoplasmII28NCT07524530
B-cell lymphomaII26NCT07593482
Diffuse large B-cell lymphomaII25NCT06500273
LymphomaII24NCT07524530
Mantle cell lymphomaII21NCT07892027
Ovarian neoplasmII18NCT03412877
Hodgkin lymphomaII17NCT03849651
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII17NCT06013423

Everything on Fludarabine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch